| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigen Presentation | 14 | 2022 | 76 | 3.400 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2020 | 226 | 3.170 |
Why?
|
| Histocompatibility Antigens Class II | 9 | 2020 | 77 | 2.970 |
Why?
|
| Calpain | 10 | 2022 | 205 | 2.750 |
Why?
|
| Spinal Cord Injuries | 8 | 2022 | 551 | 2.480 |
Why?
|
| Phosphopyruvate Hydratase | 4 | 2020 | 35 | 2.280 |
Why?
|
| Melanoma | 6 | 2022 | 335 | 1.980 |
Why?
|
| HLA-D Antigens | 5 | 2012 | 20 | 1.930 |
Why?
|
| Autophagy | 5 | 2018 | 208 | 1.600 |
Why?
|
| Triterpenes | 3 | 2018 | 40 | 1.510 |
Why?
|
| Parkinson Disease | 4 | 2022 | 272 | 1.500 |
Why?
|
| Estrogens | 6 | 2022 | 173 | 1.340 |
Why?
|
| Spinal Cord | 4 | 2022 | 244 | 1.230 |
Why?
|
| Lymphoma, B-Cell | 3 | 2015 | 40 | 1.170 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 4 | 2022 | 20 | 1.130 |
Why?
|
| Neuroprotection | 3 | 2022 | 28 | 1.040 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1070 | 1.030 |
Why?
|
| Microglia | 4 | 2021 | 143 | 1.000 |
Why?
|
| Cytokines | 11 | 2021 | 866 | 0.940 |
Why?
|
| Apoptosis | 5 | 2018 | 1641 | 0.920 |
Why?
|
| Burkitt Lymphoma | 2 | 2014 | 18 | 0.870 |
Why?
|
| Neurons | 3 | 2021 | 881 | 0.870 |
Why?
|
| Arsenic | 6 | 2021 | 46 | 0.860 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 102 | 0.860 |
Why?
|
| Neuroprotective Agents | 3 | 2021 | 317 | 0.840 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2022 | 12 | 0.810 |
Why?
|
| Parkinsonian Disorders | 2 | 2020 | 43 | 0.810 |
Why?
|
| Animals | 36 | 2022 | 20881 | 0.810 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 244 | 0.800 |
Why?
|
| Bryostatins | 2 | 2011 | 32 | 0.790 |
Why?
|
| Sulfhydryl Compounds | 1 | 2022 | 73 | 0.780 |
Why?
|
| Glioblastoma | 3 | 2011 | 219 | 0.770 |
Why?
|
| Nanoparticles | 2 | 2021 | 254 | 0.760 |
Why?
|
| Myelin Sheath | 1 | 2021 | 115 | 0.750 |
Why?
|
| Peptides | 7 | 2022 | 455 | 0.750 |
Why?
|
| Arthritis, Experimental | 2 | 2020 | 38 | 0.730 |
Why?
|
| Peptide Hormones | 1 | 2020 | 9 | 0.730 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 7 | 2018 | 133 | 0.710 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 186 | 0.700 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.700 |
Why?
|
| Inflammation | 4 | 2022 | 1030 | 0.700 |
Why?
|
| Mice | 24 | 2022 | 8474 | 0.690 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 85 | 0.680 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.680 |
Why?
|
| alpha-Synuclein | 1 | 2019 | 28 | 0.680 |
Why?
|
| RANK Ligand | 2 | 2019 | 73 | 0.670 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 236 | 0.670 |
Why?
|
| Benzamides | 1 | 2020 | 156 | 0.660 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 1851 | 0.660 |
Why?
|
| Antigen-Presenting Cells | 4 | 2020 | 50 | 0.620 |
Why?
|
| Humans | 48 | 2022 | 68618 | 0.620 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.610 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 99 | 0.610 |
Why?
|
| Immunotherapy | 3 | 2011 | 215 | 0.610 |
Why?
|
| PAX3 Transcription Factor | 1 | 2017 | 5 | 0.610 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 778 | 0.600 |
Why?
|
| Cathepsins | 3 | 2020 | 37 | 0.590 |
Why?
|
| HLA-DR4 Antigen | 3 | 2020 | 11 | 0.580 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2022 | 2083 | 0.540 |
Why?
|
| Behavior, Animal | 4 | 2019 | 470 | 0.520 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 2550 | 0.500 |
Why?
|
| Tumor Escape | 1 | 2015 | 37 | 0.490 |
Why?
|
| Mouth Neoplasms | 2 | 2019 | 206 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 629 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 90 | 0.480 |
Why?
|
| Rats | 6 | 2022 | 5300 | 0.480 |
Why?
|
| Lymphoma | 1 | 2015 | 116 | 0.470 |
Why?
|
| Substantia Nigra | 4 | 2022 | 102 | 0.450 |
Why?
|
| Mice, Inbred C57BL | 11 | 2022 | 2791 | 0.450 |
Why?
|
| Flow Cytometry | 8 | 2015 | 489 | 0.440 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 371 | 0.430 |
Why?
|
| Male | 27 | 2022 | 37321 | 0.430 |
Why?
|
| Antigens, Neoplasm | 3 | 2022 | 132 | 0.420 |
Why?
|
| Interferon-gamma | 3 | 2009 | 241 | 0.410 |
Why?
|
| Lysosomes | 3 | 2022 | 136 | 0.400 |
Why?
|
| Water Pollutants, Chemical | 4 | 2021 | 328 | 0.390 |
Why?
|
| Stilbenes | 1 | 2011 | 57 | 0.390 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 88 | 0.380 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 397 | 0.380 |
Why?
|
| Thoracic Vertebrae | 2 | 2021 | 52 | 0.370 |
Why?
|
| Butyrylcholinesterase | 2 | 2021 | 9 | 0.360 |
Why?
|
| Estradiol | 2 | 2022 | 176 | 0.350 |
Why?
|
| Tretinoin | 2 | 2007 | 92 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.350 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 659 | 0.340 |
Why?
|
| Manganese | 2 | 2019 | 26 | 0.330 |
Why?
|
| Recovery of Function | 3 | 2022 | 506 | 0.330 |
Why?
|
| Dopaminergic Neurons | 4 | 2022 | 46 | 0.320 |
Why?
|
| Glycoproteins | 4 | 2019 | 238 | 0.320 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 597 | 0.320 |
Why?
|
| Collagen Type II | 1 | 2008 | 13 | 0.320 |
Why?
|
| Chemokines | 2 | 2019 | 119 | 0.320 |
Why?
|
| Maze Learning | 5 | 2021 | 138 | 0.310 |
Why?
|
| Cell Line | 4 | 2020 | 1752 | 0.310 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 82 | 0.300 |
Why?
|
| Autoantigens | 1 | 2008 | 91 | 0.300 |
Why?
|
| Blotting, Western | 5 | 2015 | 954 | 0.300 |
Why?
|
| Dipeptides | 3 | 2018 | 89 | 0.300 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2022 | 25 | 0.290 |
Why?
|
| Environmental Exposure | 2 | 2019 | 269 | 0.290 |
Why?
|
| Multiple Sclerosis | 4 | 2016 | 132 | 0.280 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 157 | 0.280 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2020 | 105 | 0.280 |
Why?
|
| Immunosuppressive Agents | 4 | 2012 | 514 | 0.280 |
Why?
|
| Th1 Cells | 3 | 2021 | 101 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 231 | 0.270 |
Why?
|
| Asthma | 2 | 2021 | 345 | 0.270 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 271 | 0.270 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2018 | 73 | 0.270 |
Why?
|
| Bangladesh | 6 | 2021 | 14 | 0.250 |
Why?
|
| Signal Transduction | 5 | 2021 | 2689 | 0.250 |
Why?
|
| Central Nervous System | 2 | 2020 | 107 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 124 | 0.240 |
Why?
|
| Kidney | 3 | 2019 | 945 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 174 | 0.230 |
Why?
|
| Cell Survival | 2 | 2018 | 901 | 0.230 |
Why?
|
| Liver | 3 | 2019 | 1118 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 375 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 710 | 0.230 |
Why?
|
| Cell Death | 2 | 2021 | 329 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 468 | 0.220 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 565 | 0.220 |
Why?
|
| Molecular Chaperones | 2 | 2017 | 81 | 0.220 |
Why?
|
| Rotenone | 1 | 2022 | 10 | 0.210 |
Why?
|
| Biomarkers | 6 | 2019 | 1593 | 0.210 |
Why?
|
| Arsenic Poisoning | 2 | 2019 | 5 | 0.210 |
Why?
|
| Th2 Cells | 2 | 2021 | 48 | 0.210 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2022 | 8 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 852 | 0.200 |
Why?
|
| HLA Antigens | 1 | 2022 | 82 | 0.200 |
Why?
|
| Mice, Inbred DBA | 2 | 2020 | 120 | 0.200 |
Why?
|
| Immunologic Memory | 1 | 2022 | 75 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 69 | 0.190 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 42 | 0.190 |
Why?
|
| Th1-Th2 Balance | 1 | 2021 | 10 | 0.190 |
Why?
|
| Gliosis | 2 | 2020 | 51 | 0.190 |
Why?
|
| Locomotion | 1 | 2022 | 135 | 0.190 |
Why?
|
| Lead | 1 | 2021 | 45 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 110 | 0.190 |
Why?
|
| Axons | 1 | 2022 | 139 | 0.190 |
Why?
|
| Arsenites | 2 | 2019 | 8 | 0.180 |
Why?
|
| Sodium Compounds | 2 | 2019 | 10 | 0.180 |
Why?
|
| DNA Fragmentation | 2 | 2018 | 85 | 0.180 |
Why?
|
| Hormones | 1 | 2020 | 42 | 0.180 |
Why?
|
| Vaccination | 1 | 2022 | 189 | 0.180 |
Why?
|
| Environmental Pollutants | 2 | 2019 | 180 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2021 | 88 | 0.180 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2019 | 6 | 0.180 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 329 | 0.180 |
Why?
|
| Family Characteristics | 1 | 2019 | 44 | 0.170 |
Why?
|
| Myelin Basic Protein | 2 | 2018 | 62 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.170 |
Why?
|
| Rats, Long-Evans | 1 | 2020 | 203 | 0.170 |
Why?
|
| Endocytosis | 2 | 2011 | 113 | 0.170 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 65 | 0.170 |
Why?
|
| Macrophages | 2 | 2020 | 647 | 0.160 |
Why?
|
| Nervous System | 1 | 2019 | 45 | 0.160 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 37 | 0.160 |
Why?
|
| B7-1 Antigen | 2 | 2011 | 20 | 0.160 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 19 | 0.160 |
Why?
|
| Motor Activity | 1 | 2022 | 621 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 940 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 94 | 0.160 |
Why?
|
| Antimony | 1 | 2018 | 6 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2014 | 1174 | 0.150 |
Why?
|
| Aza Compounds | 1 | 2018 | 7 | 0.150 |
Why?
|
| Caspase 3 | 1 | 2018 | 233 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 756 | 0.150 |
Why?
|
| HIV Antibodies | 1 | 2018 | 28 | 0.150 |
Why?
|
| Co-Repressor Proteins | 1 | 2017 | 8 | 0.150 |
Why?
|
| CD4 Antigens | 1 | 2018 | 42 | 0.150 |
Why?
|
| Environmental Monitoring | 1 | 2019 | 180 | 0.150 |
Why?
|
| Antigens, CD | 2 | 2016 | 230 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2019 | 158 | 0.140 |
Why?
|
| Apyrase | 1 | 2016 | 10 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2011 | 237 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2018 | 111 | 0.140 |
Why?
|
| Nerve Degeneration | 2 | 2015 | 134 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2021 | 718 | 0.140 |
Why?
|
| Neuroglia | 1 | 2017 | 136 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 214 | 0.140 |
Why?
|
| Spatial Memory | 3 | 2021 | 9 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 135 | 0.130 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 95 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 658 | 0.130 |
Why?
|
| Nails | 3 | 2019 | 15 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 114 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 481 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 800 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 145 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Hair | 3 | 2019 | 46 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2016 | 765 | 0.120 |
Why?
|
| Encephalitis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 285 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2015 | 86 | 0.120 |
Why?
|
| Molecular Weight | 1 | 2014 | 358 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 511 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2014 | 35 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 284 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.110 |
Why?
|
| B7-2 Antigen | 2 | 2011 | 23 | 0.110 |
Why?
|
| Carbamates | 1 | 2014 | 41 | 0.110 |
Why?
|
| Weightlessness | 1 | 2014 | 25 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 290 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 249 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 217 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 694 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2014 | 132 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 618 | 0.110 |
Why?
|
| Interleukin-17 | 2 | 2012 | 62 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 306 | 0.100 |
Why?
|
| Peptide Fragments | 3 | 2010 | 483 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 337 | 0.100 |
Why?
|
| Melanoma, Experimental | 1 | 2012 | 95 | 0.100 |
Why?
|
| Cathepsin D | 1 | 2011 | 13 | 0.100 |
Why?
|
| Enzyme Precursors | 1 | 2011 | 27 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 76 | 0.100 |
Why?
|
| Cathepsin B | 1 | 2011 | 33 | 0.100 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2011 | 59 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2011 | 133 | 0.100 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2010 | 10 | 0.090 |
Why?
|
| Glatiramer Acetate | 4 | 2012 | 5 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2012 | 201 | 0.090 |
Why?
|
| Female | 14 | 2021 | 38074 | 0.090 |
Why?
|
| Mitochondria | 2 | 2019 | 643 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2010 | 1664 | 0.090 |
Why?
|
| HIV Infections | 1 | 2018 | 791 | 0.090 |
Why?
|
| Middle Aged | 8 | 2021 | 21147 | 0.090 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.090 |
Why?
|
| Brain | 5 | 2021 | 2176 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 1293 | 0.090 |
Why?
|
| Toxoplasma | 1 | 2009 | 23 | 0.090 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 93 | 0.080 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2007 | 6 | 0.080 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2008 | 115 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2007 | 147 | 0.070 |
Why?
|
| Protein Binding | 2 | 2007 | 1027 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 61 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 330 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 189 | 0.070 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 782 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2007 | 525 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2005 | 11 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2005 | 13 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 742 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 951 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 507 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 1038 | 0.060 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.060 |
Why?
|
| Lymph Nodes | 3 | 2012 | 258 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2004 | 117 | 0.060 |
Why?
|
| Adult | 5 | 2021 | 21403 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 209 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 1619 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 902 | 0.050 |
Why?
|
| Rats, Inbred Lew | 1 | 2022 | 150 | 0.050 |
Why?
|
| Gene Expression | 2 | 2018 | 770 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 5717 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2279 | 0.050 |
Why?
|
| Cell Separation | 2 | 2014 | 132 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2014 | 2673 | 0.050 |
Why?
|
| Body Burden | 1 | 2021 | 27 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2021 | 91 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 8912 | 0.050 |
Why?
|
| Bone Remodeling | 1 | 2021 | 45 | 0.050 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 4 | 0.050 |
Why?
|
| CD5 Antigens | 2 | 2010 | 5 | 0.050 |
Why?
|
| Spleen | 2 | 2012 | 301 | 0.050 |
Why?
|
| Antigens, CD19 | 2 | 2010 | 17 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2020 | 42 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 700 | 0.040 |
Why?
|
| Interferon beta-1a | 1 | 2019 | 4 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2019 | 12 | 0.040 |
Why?
|
| Manganese Compounds | 1 | 2019 | 8 | 0.040 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2010 | 17 | 0.040 |
Why?
|
| Chlorides | 1 | 2019 | 68 | 0.040 |
Why?
|
| Enzymes | 1 | 2019 | 25 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2019 | 26 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 41 | 0.040 |
Why?
|
| Ions | 1 | 2019 | 50 | 0.040 |
Why?
|
| Trace Elements | 1 | 2019 | 23 | 0.040 |
Why?
|
| Water Supply | 1 | 2019 | 54 | 0.040 |
Why?
|
| Drinking Water | 1 | 2019 | 33 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5731 | 0.040 |
Why?
|
| Metals | 1 | 2019 | 100 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1033 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 98 | 0.040 |
Why?
|
| Learning | 1 | 2019 | 186 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 73 | 0.040 |
Why?
|
| CD52 Antigen | 1 | 2016 | 2 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2015 | 16 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 7029 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 658 | 0.030 |
Why?
|
| Memory | 1 | 2016 | 214 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 142 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2007 | 0.030 |
Why?
|
| Weightlessness Simulation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Neoplasms | 1 | 2005 | 1667 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 41 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 160 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2014 | 64 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 568 | 0.030 |
Why?
|
| Monocytes | 1 | 2014 | 210 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Osteopontin | 1 | 2012 | 28 | 0.030 |
Why?
|
| Astrocytes | 1 | 2015 | 270 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 56 | 0.030 |
Why?
|
| Stem Cells | 1 | 2014 | 248 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2012 | 144 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Receptors, CXCR5 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2010 | 100 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2010 | 4 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2009 | 107 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 124 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2008 | 12 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2008 | 33 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 135 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 97 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4848 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2004 | 12 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 682 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2004 | 45 | 0.020 |
Why?
|
| Proline | 1 | 2004 | 52 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 49 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2004 | 165 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2004 | 99 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 948 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 29 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2004 | 136 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 35 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 322 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 420 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 317 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 362 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 532 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 929 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 282 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 546 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 636 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1745 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 14862 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 4655 | 0.010 |
Why?
|